Tempus AI, Inc. $TEM Shares Purchased by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC increased its stake in Tempus AI, Inc. (NASDAQ:TEM) by 19.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 106,073 shares of the company’s stock after acquiring an additional 17,510 shares during the quarter. Exchange Traded Concepts LLC owned approximately 0.06% of Tempus AI worth $6,264,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Cranbrook Wealth Management LLC acquired a new stake in shares of Tempus AI in the third quarter valued at about $25,000. JPL Wealth Management LLC purchased a new position in Tempus AI in the 3rd quarter valued at about $26,000. GAMMA Investing LLC purchased a new position in Tempus AI in the 3rd quarter valued at about $28,000. Harvest Fund Management Co. Ltd acquired a new stake in Tempus AI in the 3rd quarter worth about $38,000. Finally, Tsfg LLC boosted its holdings in Tempus AI by 1,515.2% in the 3rd quarter. Tsfg LLC now owns 533 shares of the company’s stock worth $43,000 after buying an additional 500 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Tempus AI

In other news, CEO Ryan Fukushima sold 9,592 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $566,407.60. Following the completion of the sale, the chief executive officer directly owned 694,354 shares in the company, valued at $41,001,603.70. This represents a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James William Rogers sold 10,084 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $595,460.20. Following the completion of the sale, the chief financial officer directly owned 101,166 shares of the company’s stock, valued at approximately $5,973,852.30. This represents a 9.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 568,841 shares of company stock worth $32,579,611. 26.27% of the stock is owned by company insiders.

Tempus AI Price Performance

TEM stock opened at $42.62 on Monday. The company has a market cap of $7.62 billion, a price-to-earnings ratio of -30.23 and a beta of 5.29. The company has a current ratio of 3.13, a quick ratio of 3.00 and a debt-to-equity ratio of 2.52. Tempus AI, Inc. has a 12 month low of $36.22 and a 12 month high of $104.32. The firm has a 50-day moving average of $55.11 and a two-hundred day moving average of $69.59.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: ARK Invest (Cathie Wood) trimmed positions in Meta and Nvidia and added to Tempus, signaling renewed institutional demand and attention that can support liquidity and investor interest. Cathie Wood’s ARK sells Meta and Nvidia stocks, buys Tempus AI
• Positive Sentiment: Tempus announced a collaboration with Daiichi Sankyo focused on ADC clinical development, reinforcing commercial partnerships in oncology that support longer‑term revenue and platform use cases. Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
• Positive Sentiment: Analysts maintain constructive views — Tempus has a consensus “Moderate Buy” rating, which may help underwrite investor confidence after recent volatility. Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Coverage pieces (Zacks/Yahoo) highlight a string of 2026 collaborations and strategic initiatives that expand Tempus’s AI/diagnostics reach; these are generally positive but are longer‑term catalysts rather than immediate earnings drivers. Tempus AI Reinforces Market Position With Collaborations in 2026
• Negative Sentiment: Zacks notes the stock is down materially since the last earnings report (about a 12.9% decline), pointing to investor concern about recent results/forward outlook and heightening short‑term selling pressure. Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?
• Negative Sentiment: Technical/volatility pressures: the stock is trading below its 50‑ and 200‑day moving averages and has a high beta, which can amplify downside moves while investors reassess fundamentals and partnership monetization timelines.

Analysts Set New Price Targets

TEM has been the subject of a number of research analyst reports. Robert W. Baird initiated coverage on Tempus AI in a report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 target price for the company. BTIG Research lowered their price target on Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Mizuho began coverage on Tempus AI in a research note on Thursday, February 19th. They issued an “outperform” rating and a $100.00 price objective for the company. Finally, JPMorgan Chase & Co. decreased their price objective on Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $78.62.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.